Screening Completed: Berlin Cures Achieves Key Milestone in BC 007 Phase II Trial for Treatment of Long COVID
BERLIN, GERMANY / ACCESSWIRE / April 23, 2024 / Berlin Cures, a pioneering clinical-stage biotechnology company, today announced the successful completion of patient screening for its pan-European Phase II trial of BC 007 (Rovunaptabin), a …